Drug Profile


Alternative Names: BAY 102; BAY-1021189; MK-1242

Latest Information Update: 21 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase I Coronary artery disease

Most Recent Events

  • 16 May 2017 Bayer initiates enrolment in a phase I relative bioavailability and food effect trial in Healthy volunteers in Germany (PO) (NCT03145038)
  • 11 May 2017 Bayer plans a phase I trial in Healthy volunteers in Germany (NCT03145038)
  • 18 Apr 2017 Phase-III clinical trials in Chronic heart failure in Ukraine, Turkey, South Africa, United Kingdom, Taiwan, Switzerland, Sweden, Singapore, Russia, Puerto Rico, Poland, Philippines, Norway, New Zealand, Netherlands, Mexico, Malaysia, South Korea, Japan, Italy, Ireland, Hong Kong, Greece, Finland, France, Denmark, Czech Republic, Colombia, Chile, Canada, Belgium, Austria, Australia, USA (PO) (NCT02861534)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top